Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

ILF3 (Q12906) - Druggability - Molecular Target Synopsis

Chain-based assessment (last updated 02/07/2019)
Domain-based assessment (last updated 30/07/2012)


Structural Druggability Help: Help

Chain-based assessment (last updated 02/07/2019)


Chains assessed3
Chains with at least one site assessed as druggable using the strict criteria0
Chains with at least one site assessed as druggable using the relaxed criteria1


		
PDB Chain Protein Name Druggable Relaxed Druggable Strict Details
2L33_A Interleukin enhancer-binding factor 3 Yes No show/hide
Site num Site Status Pickpocket Polar Ratio Surfnet Gap Vertices Buried Surfnet Long Axis Druggable Relaxed Druggable Strict
1 empty 2.15 58.7 28.9 Yes No
2 empty 2.31 59.4 27.1 No No
3 empty 2.39 70.6 10.5 No No
4 empty 2.53 47.1 9.4 No No
5 empty 1.82 58.9 8.5 No No
6 empty 3.02 69 6.3 No No
7 empty 2.88 69.3 0 No No
8 empty 2.95 74.7 0 No No
9 empty 2.55 43.8 6.3 No No
10 empty 1.98 59 4.6 No No
3P1X_A Interleukin enhancer-binding factor 3 No No show/hide
Site num Site Status Pickpocket Polar Ratio Surfnet Gap Vertices Buried Surfnet Long Axis Druggable Relaxed Druggable Strict
1 empty 1.84 62.1 19.1 No No
2 empty 2.51 63.1 13.5 No No
3 empty 2.02 74.9 11.4 No No
4 empty 2.41 66.2 10.6 No No
5 empty 2.59 72.8 7.2 No No
6 empty 2.76 71.6 5.7 No No
7 empty 1.89 63.4 7.1 No No
8 empty 2.77 59.2 5.6 No No
9 empty 3.16 67.9 0 No No
10 No No
3P1X_B Interleukin enhancer-binding factor 3 No No show/hide
Site num Site Status Pickpocket Polar Ratio Surfnet Gap Vertices Buried Surfnet Long Axis Druggable Relaxed Druggable Strict
1 empty 2.21 62.5 23.9 No No
2 empty 2.51 63.6 13.1 No No
3 empty 2.98 60.9 8.7 No No
4 empty 2.42 70.9 8 No No
5 empty 2.81 54.1 9.5 No No
6 empty 2.35 54.8 7.2 No No
7 empty 2.85 58.6 7.6 No No
8 empty 2.44 58.8 7.5 No No

Domain-based assessment (last updated 30/07/2012)


Domains assessed3
Domains assessed as druggable using the strict criteria0
Domains assessed as druggable using the relaxed criteria2

PDB (Domain) Protein Name Domain Resolution Ligands Druggable Relaxed Druggable Strict
2L33_A (3150427) Interleukin enhancer-binding factor 3 dsRBD-like, dsRNA-binding domain-like, Double-stranded RNA-binding domain (dsRBD) Yes No
3P1X_B (4122000) Interleukin enhancer-binding factor 3 dsRBD-like, dsRNA-binding domain-like, Double-stranded RNA-binding domain (dsRBD) (Homo Multimer) 1.9Å Yes No
3P1X_A (4122000) Interleukin enhancer-binding factor 3 dsRBD-like, dsRNA-binding domain-like, Double-stranded RNA-binding domain (dsRBD) (Homo Multimer) 1.9Å Yes No
3P1X_A (3660237) Interleukin enhancer-binding factor 3 dsRBD-like, dsRNA-binding domain-like, Double-stranded RNA-binding domain (dsRBD) 1.9Å No No
Ligand-based Druggability Score: -3
Ligand-based Druggability Score Percentile: 59%
Ligand-based Druggability Help: Help




		
Number of proteins in the network : 13346


ILF3 is involved in 31 interactions in the network.


Druggability
Overall Druggability Percentile: 27.73
Druggability for Cancer Therapeutics: 74.18
Druggability for Other Therapeutics: 34.93
Cancer-Associated
Cancer-associated percentile : 81.59
Network Articulation Point
Is ILF3 critical for communication in the network?


Detailed Graph Legend:Help